ArticleBMC medical imaging2023
Added value of CE-CT radiomics to predict high Ki-67 expression in hepatocellular carcinoma.
Article in BMC medical imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 9 citations in OpenAlex.
- Habitat analysis and other AI technologies for Ki-67 prediction in hepatocellular carcinoma: a multi-center study.BMC cancer · 2026Article
- A web-based prognostic nomogram incorporating VETC-associated imaging markers for predicting postoperative recurrence in hepatocellular carcinoma.BMC cancer · 2026Article
- Predictive Efficacy of a Combined Triphasic CT Radiomics and Clinical Feature Model for Ki-67 Expression in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Preoperative stratification of Ki-67 proliferation index in intrahepatic mass-forming cholangiocarcinoma via tumor-halo radiomic phenotyping on biparametric MRI: a multicenter diagnostic model.BMC medical imaging · 2025Article
- A generative vision-language model for holistic pathological assessment using preoperative imaging in hepatocellular carcinoma.EBioMedicine · 2025Article
- Emerging non-invasive imaging biomarkers of Ki-67 in pancreatic cancer: Toward predictive precision oncology.World journal of gastrointestinal oncology · 2025Article
- Evaluation and prediction of Ki-67 expression in hepatocellular carcinoma.World journal of gastrointestinal oncology · 2025Article
- Dynamic contrast-enhanced ultrasound perfusion analysis for preoperative prediction of aggressive hepatocellular carcinoma subtypes.Insights into imaging · 2025Article
- Histogram analysis of multiple mathematical diffusion-weighted imaging models for preoperative prediction of Ki-67 expression in hepatocellular carcinoma.Frontiers in oncology · 2025Article
- Radiomics predicting immunohistochemical markers in primary hepatic carcinoma: Current status and challenges.Heliyon · 2024Review
- Preoperative prediction of Ki-67 expression in hepatocellular carcinoma by spectral imaging on dual-energy computed tomography (DECT).Quantitative imaging in medicine and surgery · 2024Article
- Predicting Ki-67 expression in hepatocellular carcinoma: nomogram based on clinical factors and contrast-enhanced ultrasound radiomics signatures.Abdominal radiology (New York) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to develop a computed tomography (CT) model to predict Ki-67 expression in hepatocellular carcinoma (HCC) and to examine the added value of radiomics to clinico-radiological features.
methodsA total of 208 patients (training set, n = 120; internal test set, n = 51; external validation set, n = 37) with pathologically confirmed HCC who underwent contrast-enhanced CT (CE-CT) within 1 month before surgery were retrospectively included from January 2014 to September 2021. Radiomics features were extracted and selected from three phases of CE-CT images, least absolute shrinkage and selection operator regression (LASSO) was used to select features, and the rad-score was calculated. CE-CT imaging and clinical features were selected using univariate and multivariate analyses, respectively. Three prediction models, including clinic-radiologic (CR) model, rad-score (R) model, and clinic-radiologic-radiomic (CRR) model, were developed and validated using logistic regression analysis. The performance of different models for predicting Ki-67 expression was evaluated using the area under the receiver operating characteristic curve (AUROC) and decision curve analysis (DCA).
resultsHCCs with high Ki-67 expression were more likely to have high serum α-fetoprotein levels (P = 0.041, odds ratio [OR] 2.54, 95% confidence interval [CI]: 1.04-6.21), non-rim arterial phase hyperenhancement (P = 0.001, OR 15.13, 95% CI 2.87-79.76), portal vein tumor thrombus (P = 0.035, OR 3.19, 95% CI: 1.08-9.37), and two-trait predictor of venous invasion (P = 0.026, OR 14.04, 95% CI: 1.39-144.32). The CR model achieved relatively good and stable performance compared with the R model (AUC, 0.805 [95% CI: 0.683-0.926] vs. 0.678 [95% CI: 0.536-0.839], P = 0.211; and 0.805 [95% CI: 0.657-0.953] vs. 0.667 [95% CI: 0.495-0.839], P = 0.135) in the internal and external validation sets. After combining the CR model with the R model, the AUC of the CRR model increased to 0.903 (95% CI: 0.849-0.956) in the training set, which was significantly higher than that of the CR model (P = 0.0148). However, no significant differences were found between the CRR and CR models in the internal and external validation sets (P = 0.264 and P = 0.084, respectively).
conclusionsPreoperative models based on clinical and CE-CT imaging features can be used to predict HCC with high Ki-67 expression accurately. However, radiomics cannot provide added value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.